Is MannKind (MNKD) Undervalued After Positive INFLO 1 Data For Its IPF Pipeline?
MannKind (MNKD) has seen increased investor interest following positive Phase 1b INFLO-1 data for its inhaled nintedanib therapy, leading to a recent stock price jump. Despite short-term momentum, the stock remains down year-to-date and over a three-year period. A widely followed narrative suggests MannKind …